Duloxetine serum concentrations and clinical effects. Data from a therapeutic drug monitoring (TDM) survey

Pharmacopsychiatry

Volumn 42, Issue 5, 2009, Pages 189-193

  Waldschmitt, C ^a   Vogel, F ^a   Pfuhlmann, B ^b   Hiemke, C ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; DIAZEPAM; DULOXETINE; LITHIUM; MIRTAZAPINE; OLANZAPINE; PIPAMPERONE; QUETIAPINE; RISPERIDONE; TRIMIPRAMINE; ANTIDEPRESSANT AGENT; THIOPHENE DERIVATIVE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL GLOBAL IMPRESSION SCALE; DEPRESSION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MONITORING; FEMALE; GASTROINTESTINAL DISEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SOMNOLENCE; STEADY STATE; ULTRAVIOLET RADIATION; BLOOD; DOSE RESPONSE; HOSPITALIZATION; MIDDLE AGED; ROC CURVE; SPECTROSCOPY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; ROC CURVE; SEVERITY OF ILLNESS INDEX; SPECTRUM ANALYSIS; THIOPHENES; TREATMENT OUTCOME; ULTRAVIOLET RAYS; YOUNG ADULT;

EID: 70350517953     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0029-1220890     Document Type: Article

References (41)

1. Adli M, Pilhatsch M, Bauer M, etal. Safety of high-intensity treatment with irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression. Pharmacopsychiatry 2008 41 252-257
2. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000 58 19-36
3. Baumann P, Hiemke C, Ulrich S, etal. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004 37 243-265 (Pubitemid 39587052)
4. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, etal. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2002 25 871-880
5. Chan C, Yeo KP, Pan AX, etal. Duloxetine pharmacokinetics are similar in Japanese and Caucasian subjects. Br J Clin Pharmacol 2007 63 310-314
6. Detke MJ, Lu Y, Goldstein DJ, etal. Duloxetine, 60mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002 63 308-315 (Pubitemid 34456358)
7. Detke MJ, Wiltse CG, Mallinckrodt CH, etal. Duloxetine in the acute and long-term treatment of major depressive isorder: a placebo- and paroxetine- controlled trial. Eur Neuropsychopharmacol 2004 4 457-470
8. Everitt B, Rabe-Hesketh S. Linear mixed models I. In Analysing Medical Data Using S-PLUS New York: Springer 2001 p 243-268
9. Fava M, Mallinckrodt CH, Detke MJ, etal. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J Clin Psychiatry 2004 65 521-530
10. Fric M, Pfuhlmann B, Laux G, etal. The influence of smoking on the serum level of duloxetine. Pharmacopsychiatry 2008 41 151-155
11. Gillmann PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol 2007 151 737-748
12. Goldstein DJ, Lu Y, Detke MJ, etal. Duloxetine in the treatment of depression. A double-blind placebo-controlled comparison with paroxetine. J Clin Psychiatry 2004 24 389-399
13. Guy W. Early Clinical Drug Evaluation Unit (ECDEU) assessment manual for psychopharmacology. Revised. NIMH publication (DHEW publ No ADM 76-338) Bethesda MD: National Institute of Mental Health 1976 p 217-222
14. Hanley JA, McNeil BJ. The meaning and the use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982 143 29-36
15. Hansen RA, Gartlehner G, Lohr KN, etal. Efficacy and safety of second-generation antidepressant in the treatment of major depressive disorder. Ann Intern Med 2005 143 415-426
16. Hirschfeld RM. Efficacy of SSRIs and newer antidepressants in severe depression: comparison with TCAs. J Clin Psychiatry 1999 60 326-335
17. Hirschfeld RM, Montgomery SA, Keller MB, etal. Social functioning in depression: a review. J Clin Psychiatry 2000 61 268-275
18. Lantz RJ, Gillespie TA, Rash TJ, etal. Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos 2003 31 1142-1150
19. Lee WC, Hsiao CK. Alternative summary indices for the receiver operating characteristic curve. Epidemiology 1996 7 605-611
20. Lindell M, Karlsson MO, Lennernas H, etal. Variable expression of CYP and Pgp genes in human small intestine. Eur J Clin Invest 2003 33 493-499
21. Lingjaerde O, Ahlfors UG, Bech P, etal. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987 334 1-100
22. Lobo ED, Bergstrom RF, Reddy S, etal. In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. Clin Pharmacokinet 2008 47 191-202
23. Lopez AD, Mathers CD, Ezzati M, etal. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006 367 1747-1757
24. Lopez-Munoz F, Alamo C, Rubio G, etal. Reboxetine combination in treatment-resistant depression to selective serotonin reuptake inhibitors. Pharmacopsychiatry 2007 40 14-19
25. Mace S, Taylor D. Selective Serotonin reuptake inhibitors: a review of efficacy and tolerability in depression. Expert Opin Pharmacother 2000 1 917-933
26. MacGillivray S, Arroll B, Hatcher S, etal. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta analysis. BMJ 2003 326 1014
27. Mann K, Hiemke C, Schmidt LG, etal. Appropriateness of therapeutic drug monitoring for antidepressants in routine psychiatric inpatient care. Ther Drug Monit 2006 28 83-88
28. Montgomery SA, Baldwin DS, Blier P, etal. Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol 2007 22 323-329
29. Müller MJ, Dragicevic A, Fric M, etal. Therapeutic Drug Monitoring of tricyclic antidepressants: how does it work under clinical conditions. Pharmacopsychiatry 2003 36 98-104
30. Nierenberg AA. The treatment of severe depression: is there an efficacy gap between SSRI and TCA antidepressant generation? J Clin Psychiatry 1994 55 (Suppl A) 55-59 discussion 6061, 98100
31. Olver JS, Burrows GD, Norman TR. Third-generation antidepressants: do they offer advantages over the SSRIs? CNS Drugs 2001 15 941-954
32. Papakostas GI, Fava M, Thase ME. Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol Psychiatry 2008 63 699-704
33. Papakostas GI, Homberger CH, Fava M. A meta-analysis of clinical trial comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. J Psychopharmacol 2008 Feb 28. [Epub ahead of print]
34. Pjrek E, Willeit M, Praschak-Rieder N, etal. Treatment of seasonal affective disorder with duloxetine: an open-label study. Pharmacopsychiatry 2008 41 100-105
35. Preskorn SH, Greenblatt DJ, Flockhardt D, etal. Comparison of duloxetine, escitalopram and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. J Clin Psychopharmacol 2007 27 28-34
36. Raskin J, Goldstein DJ, Mallinckrodt CH, etal. Duloxetine in the long-term treatment of major depression disorder. J Clin Psychiatry 2003 64 1237-1244
37. Skinner MH, Kuan HY, Pan A, etal. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther 2003 73 170-177
38. Thanacoody HK, Thomas SH. Tricyclic antidepressant poisoning: cardiovascular toxicity. Toxicol Rev 2005 24 205-214
39. Ulrich S, Hiemke C, Laux G, etal. Value and actuality of the prescription information for therapeutic drug monitoring of psychopharmaceuticals: a comparison with the medico-scientific evidence. Pharmacopsychiatry 2007 40 121-127
40. Waldschmitt C, Vogel F, Maurer C, etal. Measurement of duloxetine in blood using high-performance liquid chromatography with spectrophotometric detection and column switching. Ther Drug Monit 2007 29 767-772
41. Warrington SJ. Clinical implications of the pharmacology of serotonin reuptake inhibitors. Int Clin Psychopharmacol 1992 7 (Suppl. 2) 13-19